

- generic erosion of key agents and a substantial reduction in the prescribing of Roche/Genentech/Chugai's Avastin. Decision Resources. <http://decisionresources.com/News-and-Events/Press-Releases/breast-cancer-040711-stihash.qbUy3rsq.dpuf>, April 2011,
- [0089] 17. Duval A, Buckley, N., Isherwood, A.: Breast Cancer (Event Driven), <http://bio-trends.com/Products-and-Services/Report?r=pcoron0214> Aug. 15, 2013,
- [0090] 18. DecisionBase: Breast Cancer (Triple-Negative, Advanced/Metastatic), DecisionBase; <http://decisionresources.com/Products-and-Services/Report?r=dbason0214> April 2014,
- [0091] 19. EORTC: EORTC, BIG and TESARO launch registration trial with niraparib for patients with metastatic BRCA mutated breast cancer, EORTCorg; <http://www.eortc.org/news/eortc-big-and-tesaro-launch-registration-trial-niraparib-patients-metastatic-brca-mutated-breast> November 2013,
- [0092] 20. Pohlmann P R, Mayer I A, Mernaugh R: Resistance to Trastuzumab in Breast Cancer, Clinical cancer research: an official journal of the American Association for Cancer Research 2009, 15:7479-7491
- [0093] 21. Clynes R A, Towers T L, Presta L G, Ravetch J V: Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets, Nature medicine 2000, 6:443-446
- [0094] 22. Garcia-Foncillas J, Diaz-Rubio E: Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome, Clinical & translational oncology: official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2010, 12:533-542
- [0095] 23. Pullarkat V, Deo Y, Link J, Spears L, Marty V, Curnow R, Groshen S, Gee C, Weber J S: A phase I study of a HER2/neu bispecific antibody with granulocyte-colony-stimulating factor in patients with metastatic breast cancer that overexpresses HER2/neu, Cancer Immunol Immunother 1999, 48:9-21
- [0096] 24. Repp R, van Ojik H H, Valerius T, Groenewegen G, Wieland G, Oetzel C, Stockmeyer B, Becker W, Eisenhut M, Steininger H, Deo Y M, Blijham G H, Kalden J R, van de Winkel J G, Gramatzki M: Phase I clinical trial of the bispecific antibody MDX-H210 (anti-Fc gammaRIx anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer, British journal of cancer 2003, 89:2234-2243
- [0097] 25. Curnow R T: Clinical experience with CD64-directed immunotherapy. An overview, Cancer Immunol Immunother 1997, 45:210-215
- [0098] 26. Ravetch J V, Bolland S: IgG Fc receptors, Annu Rev Immunol 2001, 19:275-290
- [0099] 27. Hamre R, Farstad I N, Brandtzaeg P, Morton H C: Expression and modulation of the human immunoglobulin A Fc receptor (CD89) and the FcR gamma chain on myeloid cells in blood and tissue, Scandinavian journal of immunology 2003, 57:506-516
- [0100] 28. Deo Y M, Sundarapandiyam K, Keler T, Wallace P K, Graziano R F: Bispecific molecules directed to the Fc receptor for IgA (Fc alpha RI, CD89) and tumor antigens efficiently promote cell-mediated cytotoxicity of tumor targets in whole blood, J Immunol 1998, 160:1677-1686
- [0101] 29. Guettinger Y, Barbin K, Peipp M, Bruenke J, Dechant M, Homer H, Thierschmidt D, Valerius T, Repp R, Fey G H, Stockmeyer B: A recombinant bispecific single-chain fragment variable specific for HLA class II and Fc alpha RI (CD89) recruits polymorphonuclear neutrophils for efficient lysis of malignant B lymphoid cells, J Immunol 2010, 184:1210-1217
- [0102] 30. Huls G, Heijnen I A, Cuomo E, van der Linden J, Boel E, van de Winkel J G, Logtenberg T: Antitumor immune effector mechanisms recruited by phage display-derived fully human IgG1 and IgA1 monoclonal antibodies, Cancer research 1999, 59:5778-5784
- [0103] 31. Lohse S, Derer S, Beyer T, Klausz K, Peipp M, Leusen J H, van de Winkel J G, Dechant M, Valerius T: Recombinant dimeric IgA antibodies against the epidermal growth factor receptor mediate effective tumor cell killing, J Immunol 2011, 186:3770-3778
- [0104] 32. Stockmeyer B, Elsasser D, Dechant M, Repp R, Gramatzki M, Glennie M J, van de Winkel J G, Valerius T: Mechanisms of G-CSF- or G M-CSF-stimulated tumor cell killing by Fc receptor-directed bispecific antibodies, Journal of immunological methods 2001, 248:103-111
- [0105] 33. van Egmond M, van Spriell A B, Vermeulen H, Huls G, van Garderen E, van de Winkel J G: Enhancement of polymorphonuclear cell-mediated tumor cell killing on simultaneous engagement of fc gammaRI (CD64) and fc alphaRI (CD89), Cancer research 2001, 61:4055-4060
- [0106] 34. Bakema J E, van Egmond M: Immunoglobulin A: A next generation of therapeutic antibodies?, mAbs 2011, 3:352-361
- [0107] 35. Stewart W W, Mazengera R L, Shen L, Kerr M A: Unaggregated serum IgA binds to neutrophil Fc alpha R at physiological concentrations and is endocytosed but cross-linking is necessary to elicit a respiratory burst, Journal of leukocyte biology 1994, 56:481-487
- [0108] 36. Low P S, Kularatne S A: Folate-targeted therapeutic and imaging agents for cancer, Current opinion in chemical biology 2009, 13:256-262
- [0109] 37. Feuerstein A: Endocyte Falls on Ovarian Cancer Drug Blowup, The Street May 2014,
- [0110] 38. Ebel W, Routhier E L, Foley B, Jacob S, McDonough J M, Patel R K, Turchin H A, Chao Q, Kline J B, Old L J, Phillips M D, Nicolaides N C, Sass P M, Grasso L: Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha, Cancer immunity 2007, 7:6
- [0111] 39. Dillman R O: Perceptions of Herceptin: a monoclonal antibody for the treatment of breast cancer, Cancer biotherapy & radiopharmaceuticals 1999, 14:5-10
- [0112] 40. Green M C, Murray J L, Hortobagyi G N: Monoclonal antibody therapy for solid tumors, Cancer treatment reviews 2000, 26:269-286
- [0113] 41. Rudnick S I, Lou J, Shaller C C, Tang Y, Klein-Szanto A J, Weiner L M, Marks J D, Adams G P: Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors, Cancer research 2011, 71:2250-2259
- [0114] 42. Stover P J: Physiology of folate and vitamin B12 in health and disease, Nutrition reviews 2004, 62:S3-12; discussion S13
- [0115] 43. Elnakat H, Ratnam M: Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy, Advanced drug delivery reviews 2004, 56:1067-1084
- [0116] 44. Parker N, Turk M J, Westrick E, Lewis J D, Low P S, Leamon C P: Folate receptor expression in